Nice (France) - Liver Disease Information

LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog has again rejected Bayer's drug Nexavar for treating liver cancer on the state health service, despite a revised charging scheme from the company.Wednesday's decision is a setback for Bayer and its partner Onyx Pharmaceuticals, which ...